Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A plus concurrent chemoradiotherapy versus durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC
jRCT2021220015Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-7684A + concurrent chemoradiotherapy followed by MK-7684A with Concurrent chemoradiotherapy followed by durvalumab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2022; status: completed.
02
Drugs
vibostolimab + pembrolizumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021220015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220015.